Waverley Pharma Inc.
Waverley Pharma Inc. is a Canadian company registered with the Companies Office of Manitoba, with its head office recorded at 4-1250 Waverley Street, Winnipeg, Manitoba R3T 6C6, and a current registry status of active. No registration number or incorporation date is available in the source registry reviewed for this profile; the company’s own website states that Waverley Pharma was founded in 2014, though this reflects a founding year reported by the company rather than a confirmed formal incorporation date.
Waverley Pharma describes itself as a specialty pharmaceutical business with two main lines of activity. The first is the development and commercialisation of generic oncology medicines: the company has reported a tentative Abbreviated New Drug Application approval from the US Food and Drug Administration for pemetrexed in November 2020, and marketing authorisations for pemetrexed, bortezomib and erlotinib in Spain, Italy, the United Kingdom and other European markets between 2018 and 2020, alongside a January 2021 tender award to supply capecitabine to NHS Scotland. Waverley Pharma also maintains an internal PARP-1 inhibitor research programme targeting novel small-molecule cancer therapeutics, and it reported a collaboration with the University of Manitoba from June 2020 on chloroquine-analogue research related to COVID-19. The company’s second line of activity is retail pharmacy: in September 2024 Waverley Pharma announced the acquisition of C & R Pharmacy, a retail pharmacy business in West Liberty, Ohio.
Waverley Pharma Inc. common shares have traded publicly on the TSX Venture Exchange under the symbol WAVE since October 2017, and the company has also been listed on the Frankfurt Stock Exchange under the symbol 5GZ since September 2020. In August 2021 the company announced a 3,000,000 Canadian dollar credit facility. Active status on the Manitoba registry does not by itself indicate that Waverley Pharma Inc. is currently trading, financially stable or compliant with any particular regulatory standard.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of Waverley Pharma Inc.
Waverley Pharma Inc. common shares have traded publicly on the TSX Venture Exchange under the symbol WAVE since October 2017, and on the Frankfurt Stock Exchange under the symbol 5GZ since September 2020, so ownership is distributed among public shareholders rather than concentrated among a small number of named private holders. The registry snapshot on file for Waverley Pharma Inc. records no named shareholders, noting only that shareholder information for Manitoba-incorporated companies has limited public disclosure. Verification against SEDAR+ continuous-disclosure filings and SEDI insider-trading records, where major or insider shareholdings for TSX Venture-listed issuers are typically reported, could not be completed for this profile because those databases could not be reached. No specific major shareholder, institutional holder or insider ownership percentage for Waverley Pharma Inc. was located in the sources reviewed.
Data availability
Shareholder and beneficial-ownership information for Waverley Pharma Inc. is classified as Not found: the company is publicly traded, meaning major and insider shareholdings would typically be disclosed through SEDI and SEDAR+ early-warning or insider filings, but no such filings could be retrieved for this profile, and the on-file Manitoba registry record does not itself list any shareholders. This should not be read as evidence that Waverley Pharma Inc. has no identifiable major shareholders.
Sources
- Companies Office, Manitoba, company registry record, last synced 11 August 2026
- waverleypharma.com, Investors page, retrieved 15 September 2026
Officers
2
Directors and officers of Waverley Pharma Inc.
The Companies Office of Manitoba record on file for Waverley Pharma Inc. lists two active officers: Larry Thiessen, MBA, as President, Chief Executive Officer and Director, and Haaris Uddin, B.Com., CPA, as Chief Financial Officer. No resignation or termination dates are recorded for either individual, and both are shown with an active work status as of the registry’s last synchronisation on 11 August 2026. Waverley Pharma’s own website separately lists a board of directors comprising Larry Thiessen (President, CEO and Director), James Kinley, CA, Albert D. Friesen, PhD, and Marcus Enns, indicating that the two-officer registry snapshot on file understates the current board; James Kinley, Albert D. Friesen and Marcus Enns do not appear in the registry data reviewed for this profile. Nationality is not disclosed for any of these individuals in either the registry record or the company’s website and should not be inferred from their names or reported addresses.
Data availability
The Manitoba registry record on file discloses officer names, roles and country-level correspondence information but not nationality or country of residence for any individual, and its coverage of the current board appears partial when checked against the company’s own website. The correspondence country recorded for both officers is Canada; no street-level correspondence address is on file, and this should not be read as either officer’s residential address.
Sources
- Companies Office, Manitoba, company registry record, last synced 11 August 2026
- waverleypharma.com, About/Team page, retrieved 15 September 2026
Registry feed — rows exactly as filed with Companies Office, Manitoba, including entries the profile above does not cover.
Group Structure
Group structure of Waverley Pharma Inc.
The registry data on file for Waverley Pharma Inc. records no current parent, subsidiary or ownership linkage. Waverley Pharma Inc.’s own official announcements, however, disclose one verified corporate relationship not present in that registry snapshot: on 23 September 2024 the company announced the acquisition of C & R Pharmacy, a retail pharmacy business based in West Liberty, Ohio, United States. This is treated here as a direct subsidiary relationship on the strength of the company’s own acquisition announcement, though Waverley Pharma has not published the acquired entity’s registration details or the exact ownership percentage acquired. No ultimate parent, indirect subsidiaries or sister companies were identified for Waverley Pharma Inc. in the sources reviewed.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| C & R Pharmacy | United States | Not disclosed | Direct subsidiary | Ownership percentage not disclosed | Active | 23 September 2024 |
Data availability
Corporate-linkage information for Waverley Pharma Inc. is partial: the Manitoba registry snapshot on file shows no linked entities at all, while the company’s own announcements independently confirm one subsidiary relationship. This should not be read as a complete picture of the group; Waverley Pharma has not disclosed whether it holds any other subsidiaries, branches or an ultimate parent.
Sources
- Companies Office, Manitoba, company registry record, last synced 11 August 2026
- Waverley Pharma Inc. official news release, “Waverley Pharma Acquires US Based Pharmacy,” 23 September 2024, waverleypharma.com, retrieved 15 September 2026
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does Waverley Pharma Inc. do?
Waverley Pharma Inc. is a specialty pharmaceutical company that develops and licenses generic oncology medicines, such as pemetrexed, bortezomib, erlotinib and capecitabine, and separately operates C & R Pharmacy, a retail pharmacy in West Liberty, Ohio, acquired in September 2024.
Where is Waverley Pharma Inc. registered?
Waverley Pharma Inc. is registered with the Companies Office of Manitoba, Canada, with its head office recorded at 4-1250 Waverley Street, Winnipeg, Manitoba R3T 6C6.
Is Waverley Pharma Inc. a public company?
Yes. Waverley Pharma Inc. common shares have traded on the TSX Venture Exchange under the symbol WAVE since October 2017, and the company has also been listed on the Frankfurt Stock Exchange under the symbol 5GZ since September 2020.
What is Waverley Pharma Inc.'s registration number?
No registration number is publicly available in the source data reviewed for this profile.
When was Waverley Pharma Inc. incorporated?
No confirmed incorporation date is available in the source data reviewed; the company's own website states it was founded in 2014.
Who is the CEO of Waverley Pharma Inc.?
Larry Thiessen, MBA, serves as President, Chief Executive Officer and Director of Waverley Pharma Inc.
Who is the Chief Financial Officer of Waverley Pharma Inc.?
Haaris Uddin, B.Com., CPA, serves as Chief Financial Officer of Waverley Pharma Inc.
Who are the directors of Waverley Pharma Inc.?
Waverley Pharma Inc.'s website lists Larry Thiessen, James Kinley, CA, Albert D. Friesen, PhD, and Marcus Enns as directors; the on-file registry record shows only Larry Thiessen with a director role.
Does Waverley Pharma Inc. have any subsidiaries?
Waverley Pharma Inc. announced the acquisition of C & R Pharmacy, a retail pharmacy in West Liberty, Ohio, on 23 September 2024; the on-file registry record does not separately list this or any other subsidiary.
Who are the shareholders of Waverley Pharma Inc.?
No specific major or insider shareholders could be verified for this profile; as a TSX Venture Exchange-listed company, Waverley Pharma Inc. shares are held by the investing public rather than disclosed as a small private shareholder register.
What products has Waverley Pharma Inc. brought to market?
Waverley Pharma Inc. has reported a tentative US FDA ANDA approval for pemetrexed, European marketing authorisations for pemetrexed, bortezomib and erlotinib between 2018 and 2020, and a January 2021 tender award to supply capecitabine to NHS Scotland.
What is Waverley Pharma Inc.'s current registry status?
The company's status on the Companies Office of Manitoba registry is recorded as active as of the last registry synchronisation on 11 August 2026.